A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
The purpose of this trial is to prospectively assess the relationship between changes in
 hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients
 receiving chemotherapy supported with Aranesp®.
Inclusion Criteria:

 -  Subjects with nonmyeloid malignancy(ies)

 -  Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy

 Exclusion Criteria:

 -  Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML),
 myelodysplastic syndromes (MDS)

 -  Unstable cardiac disease or anemia due to other causes